SMAD3, a receptor regulated SMAD (R-SMAD) is a transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinase. SMAD3 is estimated to account for at least 80% of all TGF-beta-mediated response. Activated type I receptor phosphorylates receptor-activated SMADS (RSMADS) at their c-terminal two extreme serines in the SSXS motif. The phosphorylated R-SMAD translocate into nucleus, where they regulate transcription of target genes. SMAD3 signal transduction appears to be important in the rgulation of muscle-specific genes. Loss of SMAD3 is a feature of pediatric T-cell lymphoblastic leukemia, while upregulation of SMAD3 may be responsible for TGFB hyperresponsiveness observed in scleroderma.

Target	SMAD3 (pS208)
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Tested Applications	IF/ICC, DB
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Immunogen	KLH-conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding S208 of human SMAD3.
Purification	Purified by protein G affinity chromatography. Then, the antibody fraction was peptide affinity purified in a 2-step procedure with control and phosphorylated peptides. The phospho-specific antibody was eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
Isotype	IgG
Conjugation	Unconjugated
Storage	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Swiss Prot	P84022
NCBI Accession	NP_001138574.1 NP_001138575.1 NP_001138576.1 NP_005893.1
Buffer	PBS containing 0.09% sodium azide.
UNSPSC Code	12352203
Availability	Shipped within 5-10 working days.
Note	This product is for research use only.